EUCTR2008-007785-39-DE进行中（未招募）不适用
Safety and efficacy phase I/IIa trial of an RNActive®-derived cancer vaccine in stage IIIB/IV non small cell lung cancer (NSCLC)
CureVac GmbH0 个研究点目标入组 46 人开始时间: 2008年12月19日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female and age = 18 yrs and = 75
- •2. Histologically or cytologically confirmed and documented stage IIIB/IV NSCLC
- •3. Documented stable disease or objective response according to RECIST criteria after initial chemotherapy or chemo-radiotherapy for advanced, unresectable disease:
- •Patients must have received a minimum of two cycles of standard chemotherapy, and adequate and effective radiotherapy if used in conjunction with chemotherapy (sequentially or concomitantly).
- •Prophylactic brain radiation is allowed.
- •Surgery, radiotherapy and/ or chemotherapy can have been previously administered for non-advanced disease.
- •All therapies must be completed 4 weeks before start of study treatment.
- •4. Performance status: Eastern Cooperative Oncology Group (ECOG) 0 – 1.
- •5. Life expectancy > 6 months as assessed by the investigator.
- •6. Adequate organ function:
- •Bone marrow function: hemoglobin = 100 g/L; white blood cell count (WBC) = 3.0 x 10 9/L; lymphocyte count = 1.0 x 10 9/L; absolute neutrophil count (ANC) = 1.5 x 10 9/L; platelet count = 100 x 10 9/L
- •Hepatic: aspartate transaminase (AST) and alanine transaminase (ALT) = 2.5 times upper limit of normal (ULN) (=5 x ULN if hepatic metastases present); bilirubin = 1.5 x ULN
- •Renal: creatinine = 2 mg/dL and creatinine clearance = 45 mL/min
- •7. Patients of child-producing potential must agree to use contraception while enrolled in the study and for one month after the last immunization
- •8. Written informed consent must be obtained prior to conducting any study-specific procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 22
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 24
排除标准
- •1. History of anti-cancer therapy for advanced disease other than initial chemotherapy or chemo-radiotherapy or surgery
- •2. Immunotherapy within 4 weeks prior to study enrollment, including cytokines such as granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF) or interferons
- •3. Treatment with investigational anti-cancer agents during initial therapy for advanced disease or any investigational agents within 4 weeks prior to study enrollment
- •4. Concurrent anti-tumor therapy or concurrent immunotherapy such as lectins, unspecific immunostimulants, etc.
- •5. Previous anti-cancer immunotherapy comprising RNA-transfected dendritic cells or DNA vaccines targeting any tumor-associated antigens.
- •6. Concurrent systemic steroids except topical (inhaled, topical, nasal) for the last 28 days, except replacement therapy
- •7. Concurrent major surgery or planned surgery
- •8. Prior splenectomy
- •9. Documented history of active autoimmune disorders requiring systemic immunosuppressive therapy such as sarcoidosis, lupus erythematosus, rheumatoid arthritis, glomerulonephritis or systemic vasculitis (except autoimmune thyroiditis with only thyroid hormone replacement and stable disease > 1 year)
- •10. Primary or secondary immune deficiency
- •11. Active allergy requiring continuous medication or active infections requiring anti-infectious therapy
- •12. Seropositive for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
- •13. History of other malignancies over the last 5 years (except basal cell carcinoma of the skin or carcinoma in situ of the cervix)
- •14. Uncontrolled medical condition considered as high risk for the treatment with an investigational drug including unstable diabetes mellitus, vena-cava-syndrome, known ascites and/or uncontrolled pleural effusion.
- •15. Brain metastases (symptomatic or asymptomatic) or leptomeningeal involvement
- •16. Symptomatic congestive heart failure (New York Heart Association [NYHA] 3 or 4); unstable angina pectoris within 6 months prior to enrollment; significant cardiac arrhythmia, history of stroke or transient ischemic attack
- •17. History of seizures, encephalitis or multiple sclerosis
- •18. Gastric ulcer or inflammatory bowel disease or Crohn´s disease or ulcerative colitis; no active diverticulitis
- •19. Active drug abuse or chronic alcoholism
- •20. Patients being committed to an institution by virtue of an order issued either by the judicial or the administrative authorities
研究者
相似试验
已完成
1 期
Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)Non Small Cell Lung CancerNCT00923312CureVac46
已完成
1 期
A clinical trial of SIIL's H1N1 vaccine (Inactivated) in Adults.CTRI/2010/091/000082Serum Institute of India Limited SII50
招募中
1 期
T cells and pembrolizumab for recurrent and newly diagnosed glioblastomaGlioblastoma multiforme/astrocytoma grade 4Cancer - BrainACTRN12623001126606QIMR Berghofer Medical Research Institute58
已完成
1 期
Phase I/II study on the safety and efficacy of repeated administration of FIT039 transdermal patch for verrucas caused by human papilloma-virusPhase I/II study on the safety and therapeutic efficacy of repeated administration of FIT039 transdermal patch on verrucas caused by human papillomavirusJPRN-UMIN000029695Department of Dermatology, Kyoto University Hospital44
尚未招募
不适用
A phase I clinical trial to study the safety of treatment with Tipifarnib (ZARNESTRA) combined with Bortezomib (VELCADE) in patients with myelodysplastic syndrome (MDS)myelodysplasiamyelodysplastic syndroom10018865NL-OMON30154niversitair Medisch Centrum Sint Radboud18